Navigation Links
Wound Management Technologies, Inc. Announces Strategic Business Directions, Recent Conference Presentation, in Addition to Symposium Exhibit Plans for Las Vegas

FORT WORTH, Texas, Oct. 29 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that the company is currently negotiating with several organizations looking to license WMT's proprietary activated collagen products for wound care management outside the United States.

"Wound Management Technologies has been working with various medical professionals to demonstrate how and why WMT's collagen products significantly outperform other collagen products on the market today. The positive results we have received from these demonstrations has generated both national and international interest and has provided us with the opportunity to bring in wound care organizations in different regions of the world as business partners," said Scott Haire, the company's Chief Executive Officer.

From a worldwide perspective, wound care is a $20 billion plus health care expenditure, explains the company's Chief Operations Officer, Bobby Stout. Stout added "We continue to examine existing and future partner relationships as a means to be able to achieve and maximize our revenues. By releasing additional evidence based studies and performing more clinical research, we believe we will continue to demonstrate why WMT's activated collagen products produce the best results on diabetic wounds, as well as other patients requiring wound management." CellerateRx(R), WMT's current activated collagen product, is FDA cleared for use on all wound types, except for 3rd degree burns and is effective in all wound phases.

Evidence of the efficacy of WMT's activated collagen was recently presented at the 9th annual New Cardiovascular Horizons (NCVH) and Management of the Diabetic Foot and Wound Healing conference, held September 10-13, 2008 in New Orleans. NCVH is one of the largest international multi-disciplinary conferences. The presentation was on Friday, September 12, 2008 during the session 2nd Annual New Therapeutic Wound Care Technology Summit: Emerging Use of Topical "Biologics" in Limb Salvage--Role of "Activated Collagen" in Multimodality Treatment. The entire presentation can be seen on the WMT's web site or using these links listed here:

Please click here to view Presentation:

For ALL presentations of the NCVH 2008 conference, click here:

Wound Management Technologies, Inc., also announced today that its subsidiary, Wound Care Innovations, LLC, will exhibit at the 23rd Annual Clinical Symposium on Advances in Skin and Wound Care: The Conference for Prevention and Healing at the Rio All Suite Hotel in Las Vegas, Nevada. The Symposium is designed to enable the attendee to apply basic to advanced concepts in the science of wound healing or in preventing and managing wounds. Presented will be cutting-edge treatments, emerging technologies, and research breakthroughs which will assist clinicians in identifying credible, balanced, and relevant clinical practice issues.

"This conference is an excellent opportunity for us to present our advanced wound care product, CellerateRx(R)" states Cathy Bradshaw, President of Wound Care Innovations. "We are especially excited about this conference as there were case reports using CellerateRx(R) in the August issue of the wound care journal, Advances in Skin & Wound. The Symposium allows us to target key wound care specialists from all around the United States and international attendees as well."

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at:

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Further Information:

Product Information Shareholder Relations

Cathy Bradshaw Lucy Singleton

President Secretary

954-315-9242 817-820-7080

SOURCE Wound Management Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
2. ULURU Inc. Announces Poster Presentations at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
3. Livelihood Programs Help Heal War Wounds in Uganda
4. VA, DoD Electronically Hand Off Records of Wounded Patients
5. Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009
6. Association for the Advancement of Wound Care Leads World Health Organization Initiative to Establish Guidelines for Wound and Lymphedema Care
7. Wounded Warrior Project (WWP), St. Johns University, and Insurance Industry Charitable Foundation Partner to Assist Wounded Warriors
8. Wound Management Technologies, Inc. Announces Clarification of Eprint Viewing of Case Report in Advances in Skin and Wound Journal
9. Wound Management Technologies, Inc. Announces Products to Be Registered in Taiwan
10. Michael and Terry Ward Donate $1 Million to Wounded Warrior Project (WWP)
11. Canica Design Awarded Milestone U.S. Patent for Dynamic Wound Closure Systems
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology: